Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.
- VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.
- The study found that the "diagnostic study of 71 patients with pediatric appendicitis using systems immunology methods revealed a mechanistic understanding of severe disease, indicating immune dysregulation similar to that observed in sepsis.
- The study concluded that early diagnostics and management strategies for pediatric PA should be informed by underlying immune dysregulation and similarities to sepsis.
- Based on the new potential benefits of this ER technology, we look forward to improving outcomes for children presenting with abdominal pain in the ER."